Jorge RE, Robinson RG, Arndt S, Starkstein S. Mortality and poststroke depression: a placebo controlled trial of anti-depressants. Am J Psychiatry 2003; 160:1823-1829.
* PRACTICE RECOMMENDATIONS
Treatment with either fluoxetine or nortriptyline for 12 weeks during the fir…
Giving antidepressants to stroke survivors — whether they’re depressed or not — may improve their chances of living longer.
That startling finding comes from a University of Iowa study in the October issue of the American Journal of Psychiatry .
The study included 104 stroke patients randomly assigned to receive nortriptyline (Aventyl or Pamelor), fluoxetine (Prozac) or a placebo for three months after their str…
— First Patient Dosed –
CAMBRIDGE, Mass. — CombinatoRx, Incorporated (NASDAQ: CRXX) today announced that it has begun dosing of patients in a Phase 2a clinical trial in psoriasis with CRx-191, a top…
The most effective technique for reducing the risk of developing chronic obstructive pulmonary disease (COPD) is smoking cessation. Patients with COPD who successfully stop smoking have been shown to have an improvem…
Bupropion and nortriptyline are effective adjuncts in the treatment of tobacco dependency. Both have been proved to improve abstinence rates compared to placebo. However, in the trials that studied the effectiveness of these agents, part…
One of the most preventable causes of morbidity and mortality in the United States is cigarette smoking. It was estimated that smoking-related disease would lead to more than 400,000 deaths in the United States in 2001. Smoking cessation before 50 years of age has been shown to reduce all causes of death by 50 percent in the following 16 years. Smoking cessation can increase life expectancy even in persons who sto…
